Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2

Cell Death & Disease
B XuW Wang

Abstract

Acute myeloid leukemia (AML) is a heterogeneous malignancy. Despite the advances in past decades, the clinical outcomes of AML patients remain poor. Leukemia stem cells (LSCs) is the major cause of the recurrence of AML even after aggressive treatment making, promoting development of LSC-targeted agents is an urgent clinical need. Although the antitumor activity of disulfiram (DS), an approved anti-alcoholism drug, has been demonstrated in multiple types of tumors including hematological malignancies such as AML, it remains unknown whether this agent would also be able to target cancer stem cells like LSCs. Here, we report the in vitro and in vivo activity of DS in combination with copper (Cu) against CD34+/CD38+ leukemia stem-like cells sorted from KG1α and Kasumi-1 AML cell lines, as well as primary CD34+ AML samples. DS plus Cu (DS/Cu) displayed marked inhibition of proliferation, induction of apoptosis, and suppression of colony formation in cultured AML cells while sparing the normal counterparts. DS/Cu also significantly inhibited the growth of human CD34+/CD38+ leukemic cell-derived xenografts in NOD/SCID mice. Mechanistically, DS/Cu-induced cytotoxicity was closely associated with activation of the stress-related ROS-JN...Continue Reading

References

Dec 22, 1999·Oncogene·B Rayet, C Gélinas
Nov 2, 2001·Nature·T ReyaI L Weissman
Dec 24, 2004·Journal of Medicinal Chemistry·Dazhi CenPatrick J Farmer
May 17, 2006·Journal of Clinical Psychopharmacology·Jesse J SuhCharles P O'Brien
Mar 6, 2007·Best Practice & Research. Clinical Haematology·Richard A Larson
Sep 9, 2008·Cancer Treatment Reviews·Anshul Gupte, Russell J Mumper
Oct 22, 2008·Oncogene·D N Dhanasekaran, E P Reddy
Apr 8, 2010·Free Radical Research·Geou-Yarh Liou, Peter Storz
Sep 3, 2010·The Prostate·Jianqing LinMichael A Carducci
Nov 30, 2010·Cell Stem Cell·Yoshikane KikushigeKoichi Akashi
Jan 22, 2011·Genes to Cells : Devoted to Molecular & Cellular Mechanisms·Keiko TaguchiMasayuki Yamamoto
Mar 3, 2011·Archives of Toxicology·Liam Baird, Albena T Dinkova-Kostova
Jul 7, 2011·Journal of Cellular Physiology·Gaurav Verma, Malabika Datta
Feb 11, 2012·International Journal of Cancer. Journal International Du Cancer·Concetta ConticelloFrancesco Di Raimondo
Jul 20, 2012·Nature Reviews. Cancer·Michael B Sporn, Karen T Liby
Dec 24, 2013·Antioxidants & Redox Signaling·Vitaliy O Kaminskyy, Boris Zhivotovsky
Jan 27, 2015·Current Drug Targets·Zeeshan ShaukatStephen L Gregory
Dec 15, 2015·The FEBS Journal·Tyrell CartwrightCaroline L Wilson
Mar 19, 2016·Wiley Interdisciplinary Reviews. Systems Biology and Medicine·Simon MitchellAlexander Hoffmann
Oct 7, 2016·Toxicology Research·Patricia Erebi TawariWeiguang Wang
Nov 15, 2016·Expert Review of Anticancer Therapy·Nisha Durand, Peter Storz
Jan 31, 2017·Toxicological Research·Kyoung Ah Kang, Jin Won Hyun
Mar 8, 2017·Pharmacological Reports : PR·Violetta Krajka-KuźniakWanda Baer-Dubowska
May 1, 2017·Pharmacological Reports : PR·Violetta Krajka-KuźniakWanda Baer-Dubowska

❮ Previous
Next ❯

Citations

May 9, 2019·Journal of Clinical Medicine·Priyanka Shah O'BrienAndrew M Fribley
Aug 25, 2019·Cancers·Silvia SchmidtovaLucia Kucerova
Aug 20, 2019·Current Pharmaceutical Design·Qingzhu YangHuanjie Yang
Dec 26, 2018·Oxidative Medicine and Cellular Longevity·Jiao LuoMengtao Zhou
May 3, 2020·Cellular and Molecular Life Sciences : CMLS·Anuradha KirtoniaManoj Garg
Mar 9, 2018·BioMed Research International·Xiangchou YangHong Wang
May 24, 2019·International Journal of Molecular Sciences·Mehtab KhanMyeong Ok Kim
Feb 8, 2020·Molecular Cancer·Mouradi El HoutAhmed Hamaï
Apr 11, 2019·Frontiers in Pharmacology·Petra JagustPatricia Sancho
Nov 5, 2019·Frontiers in Oncology·Sangita SridharanDayanidhi Raman
Dec 5, 2018·Redox Biology·Bernice Woon Li LeeDerrick Sek Tong Ong
Jan 12, 2021·Cancer Chemotherapy and Pharmacology·Chen LuXiao Zhang
Mar 16, 2021·Critical Reviews in Oncology/hematology·Ana Carolina B da C RodriguesDaniel P Bezerra
Jun 29, 2021·Biochimica Et Biophysica Acta. Molecular Cell Research·Ali NasrollahzadehSeyed H Ghaffari

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft
fluorescence-activated cell sorting
flow cytometry
MDS
density gradient centrifugation
FACS
electrophoresis
X-ray
PCR

Software Mentioned

SPSS
GraphPad Prism

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.